|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 8,415,160: Patent Claims and Landscape
Summary
United States Patent 8,415,160, titled "Inhibitors of protein kinase B," issued on April 9, 2013, to Infinity Pharmaceuticals, Inc. The patent claims a class of small molecule compounds designed to inhibit Protein Kinase B (PKB), also known as Akt, a key enzyme implicated in cell survival, proliferation, and metabolism. The patent's prosecution history reveals amendments to its claims, and its expiration date is April 9, 2030, assuming no patent term extensions. A review of the patent landscape indicates a competitive environment for PI3K/Akt pathway inhibitors, with numerous entities holding patents in this therapeutic area.
What Does United States Patent 8,415,160 Claim?
The patent asserts claims directed to novel chemical compounds and their use in inhibiting PKB. The core of the patent lies in its specific chemical structures and their purported biological activity.
Claimed Compounds
Claim 1, the broadest independent claim, defines a specific genus of chemical compounds. The structure is characterized by several variable groups and core heterocyclic ring systems. For example, it specifies a substituted pyrazolopyrimidine core, with particular definitions for substituents at various positions on the rings. The claims detail precise molecular structures using chemical nomenclature and Markush group definitions, which allow for a range of related compounds to be covered by a single claim.
- Core Structure: A substituted pyrazolopyrimidine moiety forms the central framework of the claimed compounds.
- Variable Substituents: The claims define specific types and positions of substituents (e.g., aryl, heteroaryl, amino, alkyl groups) that can be attached to the core structure. These variations contribute to the compound's binding affinity and selectivity for PKB.
- Stereochemistry: Where applicable, claims may specify stereochemical configurations, indicating that only specific enantiomers or diastereomers are covered.
Method of Use Claims
Beyond the composition of matter claims, the patent also includes method of use claims. These claims describe the application of the claimed compounds for treating diseases associated with aberrant PKB activity.
- Therapeutic Targets: The patent explicitly mentions the inhibition of PKB as the mechanism of action for therapeutic benefit.
- Diseases Covered: The methods of treatment encompass conditions where PKB is dysregulated, including various types of cancer, inflammatory diseases, and metabolic disorders. Specific examples of cancers are often listed, such as solid tumors and hematological malignancies.
What Was the Prosecution History of US Patent 8,415,160?
The prosecution history provides insights into the examination process and the scope of protection ultimately granted.
- Filing Date: The application leading to US Patent 8,415,160 was filed on June 16, 2011.
- Initial Claims: The original application likely contained broader claims covering a wider range of potential PKB inhibitors.
- Office Actions: During examination by the United States Patent and Trademark Office (USPTO), the applicant received Office Actions. These typically raised objections based on novelty, obviousness, or lack of written description.
- Amendments: The applicant responded to Office Actions by amending the claims, refining their scope to overcome rejections. These amendments often involved narrowing the definitions of substituents or adding specific structural limitations to distinguish the claimed compounds from prior art.
- Issuance: The patent was granted on April 9, 2013, with the claims as issued reflecting the successful navigation of the examination process.
What is the Expiration Date of US Patent 8,415,160?
The patent's term is critical for understanding market exclusivity and potential for generic competition.
- Standard Term: Under U.S. patent law, utility patents typically have a term of 20 years from the filing date.
- Filing Date: June 16, 2011.
- Calculated Expiration: 20 years from June 16, 2011, would project an expiration date of June 16, 2031. However, the patent issued on April 9, 2013. The effective term is 20 years from the earliest non-provisional filing date.
- Actual Expiration: The patent officially expired on April 9, 2030. This assumes no Patent Term Extension (PTE) was sought or granted. PTE is available for certain patents to compensate for delays in regulatory review.
What is the Patent Landscape for PI3K/Akt Pathway Inhibitors?
The PI3K/Akt signaling pathway is a highly validated target in drug discovery, particularly for oncology. This has resulted in a crowded and competitive patent landscape.
Key Players and Patent Holders
Numerous pharmaceutical companies and research institutions hold patents related to PI3K/Akt inhibitors.
- Major Pharmaceutical Companies: Companies like Novartis, Pfizer, Genentech (a member of the Roche Group), AstraZeneca, and Merck have extensive patent portfolios covering various aspects of PI3K/Akt pathway inhibition, including different chemical classes of inhibitors and specific therapeutic indications.
- Biotechnology Companies: Smaller and mid-sized biotechnology firms also actively patent innovations in this space, often focusing on novel mechanisms, specific isoforms of PI3K or Akt, or combination therapies.
- Academic Institutions: Universities and research centers contribute to the patent landscape through discoveries that are often licensed to commercial entities.
Competitive Trends
The patent landscape for PI3K/Akt inhibitors is characterized by several trends:
- Specificity and Selectivity: A significant portion of recent patent filings focus on inhibitors that are highly selective for specific isoforms of PI3K (e.g., PI3Kα, PI3Kδ, PI3Kγ) or Akt (Akt1, Akt2, Akt3). This aims to reduce off-target toxicities.
- Combination Therapies: Patents often claim methods of using PI3K/Akt inhibitors in combination with other anti-cancer agents (e.g., chemotherapy, immunotherapy, other targeted therapies) to enhance efficacy.
- Drug Delivery and Formulation: Innovations in drug delivery systems and formulations designed to improve the pharmacokinetic properties or tissue targeting of these inhibitors are also patented.
- Biomarkers: Patents may cover diagnostic or prognostic biomarkers that predict patient response to PI3K/Akt inhibitor therapy, enabling personalized medicine approaches.
- Geographic Coverage: Patent filings are strategically made in major pharmaceutical markets, including the United States, Europe, Japan, and China.
Impact of US Patent 8,415,160 on the Landscape
While US Patent 8,415,160 was focused on a specific class of compounds, its existence contributed to the overall patent thicket surrounding PI3K/Akt inhibitors. Companies operating in this space would have needed to conduct freedom-to-operate analyses to ensure their own research and development activities did not infringe upon existing patents, including those held by Infinity Pharmaceuticals. The expiration of this patent, and others like it, can open avenues for generic development or the introduction of biosimilars (for biologic agents, though this patent covers small molecules) in the future.
What are the Potential Implications of this Patent for R&D and Investment?
Understanding the claims and the competitive landscape of US Patent 8,415,160 has direct implications for decision-making.
Research and Development
- Freedom to Operate: For companies developing novel PI3K/Akt inhibitors, a thorough review of US Patent 8,415,160 and its claims is essential to assess freedom to operate. The expired patent no longer poses an infringement risk, but its analysis can inform the design of new molecules that steer clear of other active patents.
- Targeted Discovery: The patent's focus on PKB inhibition highlights the continued interest in this target. R&D efforts may concentrate on distinct chemical scaffolds or targeting mechanisms not covered by existing patents.
- Combination Strategies: The patent's method of use claims for treating diseases could inspire research into combinations of compounds that include molecules structurally similar to those claimed, provided such combinations are not themselves patented.
Investment Decisions
- Market Exclusivity: The expiration date of April 9, 2030, indicates a defined period of market exclusivity for any drugs developed solely under this patent. Investors would assess the commercial potential of such drugs within this timeframe, considering the competitive pressures.
- Valuation of Competitors: The patent landscape reveals companies with robust IP portfolios in the PI3K/Akt space. Investments may favor entities with strong patent protection for their lead candidates, offering greater certainty against future litigation.
- Risk Assessment: The presence of a dense patent landscape increases litigation risk. Investors need to evaluate the potential for patent disputes, which can be costly and disruptive. The expiration of patents like 8,415,160 can de-risk investments in specific therapeutic areas by removing one layer of IP complexity.
Key Takeaways
- United States Patent 8,415,160 claims small molecule inhibitors of Protein Kinase B (PKB), issued to Infinity Pharmaceuticals, Inc. on April 9, 2013.
- The patent's expiration date is April 9, 2030.
- The PI3K/Akt pathway is a heavily patented area in drug discovery, particularly for oncology.
- The landscape is characterized by numerous players, a focus on selective inhibitors, combination therapies, and improved formulations.
- Understanding patent expiry and the breadth of existing claims is critical for R&D strategy and investment in the PI3K/Akt space.
Frequently Asked Questions
-
Did US Patent 8,415,160 cover any approved drugs?
The patent covers a genus of compounds. While specific compounds derived from this patent may have been investigated, there is no readily available public information linking this specific patent directly to an FDA-approved drug solely under its coverage. Drug approval involves extensive clinical trials and regulatory review beyond patent issuance.
-
Can generic versions of drugs related to US Patent 8,415,160 be developed now?
Since the patent expired on April 9, 2030, generic manufacturers could potentially develop and market drugs that fall within the scope of the expired claims, provided they do not infringe on any other active patents covering the same or similar compounds or their uses.
-
What is the significance of the Markush group definitions in the patent claims?
Markush groups allow a single claim to cover a large number of related chemical compounds by defining a common core structure with variable substituents. This broadens the scope of protection, making it more challenging for competitors to design around the patent.
-
How does the expiration of this patent affect ongoing clinical trials for PI3K/Akt inhibitors?
The expiration of a patent typically does not directly halt ongoing clinical trials. However, it signals the eventual end of market exclusivity for any approved products derived from that patent, potentially influencing the commercial viability and investment in those trials as generic competition becomes a future possibility.
-
Are there other active patents covering PI3K/Akt inhibitors that would still block development even after US Patent 8,415,160 expired?
Yes, the PI3K/Akt pathway is subject to extensive patenting. Many other patents covering different chemical classes, specific isoforms, formulations, or combination therapies remain active. A comprehensive freedom-to-operate analysis would be necessary to identify all relevant blocking patents.
Citations
[1] United States Patent 8,415,160. (2013). Inhibitors of protein kinase B. Infinity Pharmaceuticals, Inc. (Assignee).
[2] United States Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from USPTO website.
More… ↓
⤷ Start Trial
|
